Novo Nordisk (NVO.N) CEO: Wegovy oral tablets still account for approximately 80% of new oral patient initiation rates.

2026-11-04

Novo Nordisk (NVO.N) CEO: Wegovy oral tablets still account for approximately 80% of new oral patient initiation rates.